Biotech

Companies & Industries

Biotech Companies & Industries Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 19.10.2022.

Biotechnology
Medicine
Microbiology
G-20 major economies
Public relations
Leukemia

@NatureBiotech shared
On Oct 16, 2022
RT @OneNucleus: Is Technology Diversifying Biomedical R&D Outputs? Discussing this at #GenesisLondon life science conference on 7 December in London, will be speakers from @NatureBiotech, @precisionlifeAI, @benevolent_ai, @iesogroup, @ELIXIREurope Read more here https://t.co/LDaKX3OwAg https://t.co/Tgzqg3yX84
Open
Is Technology Diversifying Biomedical R&D Outputs?

Is Technology Diversifying Biomedical R&D Outputs?

With advances in technology and their adoption occurring faster than ever before in all aspects of our lives, it is perhaps surprising that the field of biotechnology is only fairly ...

@PharmaScrip shared
On Oct 15, 2022
Enliven Takes Precision Oncology Ambitions Public In Merger With Imara https://t.co/mgoEsDbaJn #PharmaScrip
Open
Enliven Takes Precision Oncology Ambitions Public In Merger With Imara

Enliven Takes Precision Oncology Ambitions Public In Merger With Imara

<p>The planned all-stock transaction will enable Enliven to take over Imara’s Nasdaq listing with cash runway into 2026. Imara shareholders get contingent value rights tied to sold-off top ...

@IAmBiotech shared
On Oct 17, 2022
Don't miss the chance to showcase your thought leadership on the biggest biotech stage in the world by submitting a #BIO2023 session proposal before the extended deadline of October 20, 2022. https://t.co/1LGCw3k95z
Open
Now Accepting Call For Sessions Proposals for the 2023 BIO International Convention

Now Accepting Call For Sessions Proposals for the 2023 BIO International Convention

Now Accepting Call For Sessions Proposals for the 2023 BIO International Convention   Showcase your thought leadership by speaking on or helping build a panel for the BIO 2023 program by ...

@PharmaScrip shared
On Oct 19, 2022
BeiGene's Brukinsa PFS Win Lifts China Biotech Stocks https://t.co/NBfySivXdw #PharmaScrip
Open
BeiGene's Brukinsa PFS Win Lifts China Biotech Stocks

BeiGene's Brukinsa PFS Win Lifts China Biotech Stocks

<p><span>BeiGene's Brukinsa beats Imbruvica in top-line progression-free survival results from the Phase III head-to-head ALPINE trial in chronic lymphocytic leukemia or small lymphocytic ...

@matthewherper shared
On Oct 17, 2022
Treeline, Josh Bilenker's next biotech, has raise a lot of money. We have almost as many questions. By me and ⁦@ADeAngelis_bio⁩. https://t.co/CDewfmgZ0w
Open
Josh Bilenker’s last biotech sold for $8 billion. His next one is cloaked in mystery but loaded with money

Josh Bilenker’s last biotech sold for $8 billion. His next one is cloaked in mystery but loaded with money

The big fundraising effort by Josh Bilenker and Jeffrey Engelman is likely to seed even more curiosity about what, exactly, is happening at their new company, Treeline.

@PharmaScrip shared
On Oct 14, 2022
SillaJen Soars As Korea Exchange Decides To Retain Listing https://t.co/9MgtU4L8vW #PharmaScrip
Open
SillaJen Soars As Korea Exchange Decides To Retain Listing

SillaJen Soars As Korea Exchange Decides To Retain Listing

<p>The long-standing SillaJen saga in Korea appears close to ending following a decision that the company can maintain its stock market listing. Shares in the oncolytic virus firm surged by ...

@DNABARCODE shared
On Oct 16, 2022
RT @EricTopol: "There are now 95 nasal vaccines under development around the world.... 6 have reached the final Phase 3 in clinical trials." None of those late trials are in the US. India and China already have approved nasal/inhaled vaccines https://t.co/mVwaXZ9vne @carmenpaun @adamcancryn https://t.co/ix6zZYqun7
Open
Without a nasal vaccine, the U.S. edge in fighting Covid is on the line

Without a nasal vaccine, the U.S. edge in fighting Covid is on the line

Foreign rivals are developing vaccines that could stop transmission before the U.S., and that’s a potential biosecurity threat.

@LillyPad shared
On Oct 18, 2022
Our latest proposed acquisition could accelerate gene therapies that aim to restore, improve, and preserve hearing for patients living with disabling hearing loss worldwide. Read more here: https://t.co/2EVmhHjAY9 https://t.co/5meGkSWLux
Open
Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss

Lilly to Acquire Akouos to Discover and Develop Treatments for Hearing Loss

The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.